Tirzepatide, a dual glucagon-like peptide-1 and gastric inhibitory peptide receptor agonist, is also widely used to treat T2D, obesity, and sleep apnea syndrome caused by severe obesity. Here, GCG is linked to type 2 diabetes mellitus.